127 related articles for article (PubMed ID: 15883179)
41. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
42. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes.
Narreddy S; Manavathu E; Chandrasekar PH; Alangaden GJ; Revankar SG
J Antimicrob Chemother; 2010 Apr; 65(4):701-3. PubMed ID: 20130026
[TBL] [Abstract][Full Text] [Related]
43. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.
Guembe M; Guinea J; Peláez T; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2007 Sep; 51(9):3457-8. PubMed ID: 17576835
[No Abstract] [Full Text] [Related]
46. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.
Vitale RG; de Hoog GS; Schwarz P; Dannaoui E; Deng S; Machouart M; Voigt K; van de Sande WW; Dolatabadi S; Meis JF; Walther G
J Clin Microbiol; 2012 Jan; 50(1):66-75. PubMed ID: 22075600
[TBL] [Abstract][Full Text] [Related]
47. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus.
Ganesan LT; Manavathu EK; Cutright JL; Alangaden GJ; Chandrasekar PH
Clin Microbiol Infect; 2004 Nov; 10(11):961-6. PubMed ID: 15521997
[TBL] [Abstract][Full Text] [Related]
48. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.
Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2005 Nov; 56(5):887-92. PubMed ID: 16188916
[TBL] [Abstract][Full Text] [Related]
49. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Dannaoui E; Meis JF; Loebenberg D; Verweij PE
Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
[TBL] [Abstract][Full Text] [Related]
50. A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.
Krishnan-Natesan S; Manavathu EK; Alangaden GJ; Chandrasekar PH
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):361-4. PubMed ID: 19302924
[TBL] [Abstract][Full Text] [Related]
51. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
Steinbach WJ; Singh N; Miller JL; Benjamin DK; Schell WA; Heitman J; Perfect JR
Antimicrob Agents Chemother; 2004 Dec; 48(12):4922-5. PubMed ID: 15561883
[TBL] [Abstract][Full Text] [Related]
52. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry.
Pina-Vaz C; Costa-de-Oliveira S; Rodrigues AG; Espinel-Ingroff A
J Clin Microbiol; 2005 Sep; 43(9):4674-9. PubMed ID: 16145125
[TBL] [Abstract][Full Text] [Related]
53. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
Ullmann AJ
Curr Med Res Opin; 2003; 19(4):263-71. PubMed ID: 12841918
[TBL] [Abstract][Full Text] [Related]
54. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran.
Vaezi A; Walther G; Kurzai O; Mahdi D; Dadashzadeh M; Nasri E; Diba K; Badali H; Fakhim H
Mycoses; 2021 Jul; 64(7):780-787. PubMed ID: 33835599
[TBL] [Abstract][Full Text] [Related]
55. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus.
Manavathu EK; Alangaden GJ; Chandrasekar PH
J Antimicrob Chemother; 2003 Jun; 51(6):1423-5. PubMed ID: 12716776
[TBL] [Abstract][Full Text] [Related]
56. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
57. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.
Otcenásek M; Buchta V
Mycopathologia; 1994 Dec; 128(3):135-7. PubMed ID: 7739727
[TBL] [Abstract][Full Text] [Related]
58. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
59. Unexplained increase in Paecilomyces variotii blood culture isolates in the UK.
Lamagni TL; Campbell C; Pezzoli L; Johnson E
Euro Surveill; 2006 Nov; 11(11):E061116.2. PubMed ID: 17213552
[No Abstract] [Full Text] [Related]
60. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
